Clinical Trials Logo
  1. Home
  2. Growth Hormone Deficiency
  3. NCT03327207
  4. Details
NCT03327207 Clinical Trial

Exploring Interactions Between Growth Hormone and the Microbiome

Growth Hormone Deficiency Clinical Trial

Official title:
Exploring Interactions Between Growth Hormone and the Microbiome

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03327207
Other study ID # 0132-17 RMB CTIL
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2017
Est. completion date November 2021

Study information
Verified date July 2020
Source Rambam Health Care Campus
Contact Smadar Shilo, Dr
Phone 89344307
Email smadar.shilo@weizmann.ac.il
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to characterize the microbiome and metabolomics of children with Growth Hormone (GH) deficiency, prior GH treatment initiation and compare it to healthy children

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date November 2021
Est. primary completion date November 2021
Accepts healthy volunteers
Gender All
Age group 3 Years to 18 Years
Eligibility Inclusion Criteria:

- Children with GH deficiency

Exclusion Criteria:

- Turner syndrome

- End state renal disease (ESRD)

- Prader-Willi syndrome

- Systemic illness

- Antibiotics/Antifungal in the last 3m

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Non Interventional
Non Interventional

Locations
Country Name City State
Israel Pediatric endocrinology unit rambam medical center Haifa

Sponsors (2)
Lead Sponsor Collaborator
Rambam Health Care Campus Weizmann Institute of Science

Country where clinical trial is conducted

Israel, 

Outcome
Type Measure Description Time frame Safety issue
Primary Changes in the microbiome population following Growth hormone treatment 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT02243852 - Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) N/A
Completed NCT01440686 - Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Phase 1
Completed NCT00990340 - Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method Phase 4
Completed NCT00149708 - Consequence of Lifetime Isolated Growth Hormone Deficiency N/A
Completed NCT00235599 - The IGFBP-3 Stimulation Test: A New Tool for the Diagnosis of Growth Hormone Deficiency in Children. N/A
Completed NCT00459940 - The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients N/A
Completed NCT01157793 - A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood Phase 4
Completed NCT00004365 - Study of Pituitary Size and Function in Familial Dwarfism of Sindh N/A
Recruiting NCT00227253 - Chromosome 18 Clinical Research Center
Recruiting NCT04121780 - Growth Hormone Replacement Therapy for Retried Professional Football Players Phase 2
Completed NCT02934399 - Dynamic Hormone Diagnostics in Endocrine Disease
Completed NCT01090778 - Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I) Phase 2
Completed NCT00965484 - Genotropin Study Assessing Use of Injection Pen Phase 3
Completed NCT01062529 - Peripheral Metabolic Effects of Somatostatin N/A
Completed NCT00616278 - National Cooperative Growth Study in CKD N/A
Completed NCT02693522 - Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency Phase 3
Recruiting NCT02908958 - Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Phase 4
Terminated NCT01243892 - A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device N/A
Withdrawn NCT00638287 - Inter-Assay Growth Hormone and IGF-I Variability N/A
Completed NCT00957671 - Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Phase 4